Evidence map›Paper›PMID 41061137›Full record

ArticleJMIR human factors2025

Text Messaging Between Patients With Inflammatory Rheumatic Diseases and Pharmacists to Solve Drug-Related Problems: Prospective Feasibility Study.

Lex L Haegens, Charlotte L Bekker, Marcel Flendrie, Bart J F van den Bemt, Victor J B Huiskes

Abstract read
In one paragraph

Article in JMIR human factors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lex L HaegensDepartment of Research, Sint Maartenskliniek, Hengstdal 3, Ubbergen, 6574NA, The Netherlands, 31 683833157.ORCID 0000-0003-1850-4365
Charlotte L BekkerDepartment of Pharmacy, Radboudumc, Nijmegen, The Netherlands.ORCID 0000-0002-6018-4409
Marcel FlendrieDepartment of Rheumatology, Sint Maartenskliniek, Ubbergen, The Netherlands.ORCID 0000-0001-9944-4389
Bart J F van den BemtDepartment of Research, Sint Maartenskliniek, Hengstdal 3, Ubbergen, 6574NA, The Netherlands, 31 683833157.ORCID 0000-0002-8560-9514
Victor J B HuiskesDepartment of Pharmacy, Radboudumc, Nijmegen, The Netherlands.ORCID 0000-0002-2120-354X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients with inflammatory rheumatic diseases often experience drug-related problems (DRPs). As these can result in negative health consequences, DRPs should be identified and addressed in a timely manner. Text messaging between patients and pharmacists at the initiative of the patient has the potential to deliver support with DRPs more continuously, increase accessibility and efficiency, and enhance patient involvement in the process of identifying and solving DRPs. Objective: This study aimed to assess the feasibility of text messaging from both the patients' and health care practitioners' perspectives before a large-scale implementation. Methods: Adult patients using a disease-modifying antirheumatic drug were given access to text messaging with pharmacists to discuss DRPs for a period of 8 weeks. Patients received a response from a pharmacist within 4 working hours. Feasibility was evaluated based on five domains of Bowen's framework for designing feasibility studies: (1) demand: actual use, expressed interest (user version of the Mobile Application Rating Scale - section E), and factors impacting future use; (2) limited efficacy: number of DRPs solved, DRPs resulting in follow-up, and DRPs warranting involvement of health care provider; (3) implementation: degree of execution (number of conversations answered within service level) and resources needed (pharmacists' time investment per conversation); (4) acceptability: satisfaction and appropriateness (theoretical framework of acceptability); and (5) practicality: ability to carry out intervention activities (System Usability Scale). Data were collected by means of usage data and a questionnaire. Results: In total, 45 patients (median age 57, IQR 52-65 y; n=31, 69% female) and 5 pharmacists (median age 41, IQR 26-47 y; n=1, 20% female) actively participated in this study. In the demand domain, 158 unique DRPs were raised in 133 conversations, with a median of 3 (IQR 2-4) unique DRPs per patient. Expressed interest was rated high by patients (median 4, IQR 4-5), and 90% (37/41) of patients would recommend text messaging to others. In the limited-efficacy domain, all DRPs were solved, and 77% (122/158) of DRPs warranted involvement of a health care provider. In the implementation domain, 87% (116/133) of conversations were answered within the promised timeframe with a median time investment of 4:15 (IQR 2:21-7:27) minutes per conversation. Acceptability was rated high by patients (median 4, IQR 4-5) and pharmacists (median 5, IQR 4-5). Finally, in the practicality domain, System Usability Scale was scored above average for patients (mean 72, SD 18) and pharmacists (mean 81, SD 16). Conclusions: Text messaging with pharmacists at the initiative of patients with rheumatic diseases seems feasible for discussing DRPs in terms of limited efficacy, implementation, acceptability, demand, and practicality for patients and pharmacists.

Indexed as

Antirheumatic AgentsDrug-Related Side Effects and Adverse ReactionsPharmacistsRheumatic DiseasesText MessagingAdultAgedFeasibility StudiesFemaleHumansMaleMiddle AgedProspective StudiesAntirheumatic Agentsdigital healthdisease-modifying antirheumatic drugDRPsdrug-related problemsfeasibilityinflammatoryinflammatory rheumatic diseasesmHealthmobile healthquestionnairesrheumatic diseasestext messaging

Identifiers

PMID41061137
PMCPMC12507129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.